|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
381,510,000 |
Market
Cap: |
169.20(M) |
Last
Volume: |
4,513,016 |
Avg
Vol: |
4,470,766 |
52
Week Range: |
$0.4435 - $1.19 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
525,000 |
525,000 |
Total Buy Value |
$0 |
$0 |
$343,050 |
$343,050 |
Total People Bought |
0 |
0 |
2 |
2 |
Total Buy Transactions |
0 |
0 |
2 |
2 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wiinberg Ulf |
Director |
|
2018-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,915 |
45,915 |
|
- |
|
Corvese Brian |
Director |
|
2018-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,220 |
21,220 |
|
- |
|
Wright Timothy |
Director |
|
2018-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,915 |
17,581 |
|
- |
|
Valentine Karen |
Chief Legal Officer |
|
2017-12-12 |
4 |
S |
$3.46 |
$28,921 |
D/D |
(8,358) |
101,521 |
|
- |
|
Baysal Ozer |
Chief Commercial Officer |
|
2017-12-12 |
4 |
S |
$3.46 |
$12,846 |
D/D |
(3,712) |
58,790 |
|
- |
|
Klaskin Christine M |
VP, Finance |
|
2017-12-12 |
4 |
S |
$3.46 |
$19,418 |
D/D |
(5,610) |
64,333 |
|
- |
|
Buell Jennifer |
Chief Communications Officer |
|
2017-12-12 |
4 |
S |
$3.46 |
$12,152 |
D/D |
(3,511) |
35,656 |
|
- |
|
Duncan Alex |
Chief Technology Officer |
|
2017-12-12 |
4 |
S |
$3.46 |
$22,651 |
D/D |
(6,546) |
21,026 |
|
- |
|
Armen Garo H |
Chairman and CEO |
|
2017-11-30 |
4 |
D |
$3.96 |
$1,188,000 |
D/D |
(300,000) |
1,290,441 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2017-10-30 |
4/A |
B |
$3.61 |
$145,853 |
D/D |
40,388 |
1,590,441 |
2.74 |
- |
|
Armen Garo H |
Chairman and CEO |
|
2017-10-30 |
4 |
A |
$3.61 |
$145,853 |
D/D |
40,388 |
1,590,441 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2017-10-27 |
4/A |
B |
$3.51 |
$209,262 |
D/D |
59,612 |
1,550,053 |
2.74 |
- |
|
Armen Garo H |
Chairman and CEO |
|
2017-10-27 |
4 |
A |
$3.51 |
$209,262 |
D/D |
59,612 |
1,550,053 |
|
- |
|
Valentine Karen |
Chief Legal Officer |
|
2017-10-09 |
4 |
A |
$3.59 |
$89,118 |
D/D |
24,824 |
109,879 |
|
- |
|
Baysal Ozer |
Chief Commercial Officer |
|
2017-10-09 |
4 |
A |
$3.59 |
$46,957 |
D/D |
13,080 |
62,502 |
|
- |
|
Klaskin Christine M |
VP, Finance |
|
2017-10-09 |
4 |
A |
$3.59 |
$37,447 |
D/D |
10,431 |
69,943 |
|
- |
|
Buell Jennifer |
Chief Communications Officer |
|
2017-10-09 |
4 |
A |
$3.59 |
$37,447 |
D/D |
10,431 |
39,167 |
|
- |
|
Armen Garo H |
CEO and Chairman of the Board |
|
2017-10-09 |
4 |
A |
$3.59 |
$258,358 |
D/D |
71,966 |
1,362,407 |
|
- |
|
Duncan Alex |
Chief Technology Officer |
|
2017-10-09 |
4 |
A |
$3.59 |
$48,189 |
D/D |
13,423 |
27,572 |
|
- |
|
Buell Jennifer |
VP Research & External Affairs |
|
2017-09-03 |
4 |
A |
$3.72 |
$16,275 |
D/D |
4,375 |
28,736 |
|
- |
|
Duncan Alex |
Chief Technology OfficerOffice |
|
2017-06-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,149 |
|
- |
|
Buell Jennifer |
VP Research & External Affairs |
|
2017-06-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
24,361 |
|
- |
|
Klaskin Christine M |
VP, Finance |
|
2017-04-19 |
4 |
D |
$3.39 |
$12,655 |
D/D |
(3,733) |
59,512 |
|
- |
|
Klaskin Christine M |
VP, Finance |
|
2017-04-19 |
4 |
A |
$3.39 |
$35,354 |
D/D |
10,429 |
63,245 |
|
- |
|
Baysal Ozer |
Chief Business Officer |
|
2017-04-19 |
4 |
D |
$3.39 |
$11,997 |
D/D |
(3,539) |
49,422 |
|
- |
|
186 Records found
|
|
Page 5 of 8 |
|
|